Apellis Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	396.59	75.42	66.56	250.65	0	0	0	0	0
Revenue Growth (YoY)	425.83%	13.31%	-73.44%	-	-	-	-	-	-
Cost of Revenue	58.51	5.64	0.2	0	0	0	0	0	0
Gross Profit	338.08	69.79	66.36	250.65	0	0	0	0	0
Selling, General & Admin	500.82	277.16	176.77	139.4	67.05	22.64	10.46	4.3	6.36
Research & Development	354.39	387.24	345.87	299.92	220.97	105.29	40.3	22.98	13.73
Other Operating Expenses	0	0	80	25.05	0	0	0.14	-0.02	26.48
Operating Expenses	855.2	664.4	602.64	464.37	288.02	127.93	50.91	27.26	46.57
Operating Income	-517.12	-594.61	-536.28	-213.73	-288.02	-127.93	-50.91	-27.26	-46.57
Interest Expense / Income	29.58	32.63	13.24	29.94	5.29	2.51	0.37	0	-0.05
Other Expense / Income	-20.21	24.26	196.48	99.37	11.41	-2.94	-0.28	-0.14	-
Pretax Income	-526.5	-651.5	-746	-343.03	-304.71	-127.5	-51.01	-27.12	-46.52
Income Tax	2.13	0.67	0.35	1.85	0	0	0	0	0
Net Income	-528.63	-652.17	-746.35	-344.87	-304.71	-127.5	-51.01	-27.12	-46.52
Shares Outstanding (Basic)	119	106	84	75	62	54	14	8	6
Shares Outstanding (Diluted)	119	106	84	75	62	54	14	8	6
Shares Change	11.84%	25.70%	12.32%	20.78%	14.40%	292.16%	64.57%	45.44%	-
EPS (Basic)	-4.45	-6.15	-8.84	-4.59	-4.90	-2.34	-3.68	-3.22	-8.03
EPS (Diluted)	-4.45	-6.15	-8.84	-4.59	-4.90	-2.34	-3.68	-3.22	-8.03
Free Cash Flow	-595.41	-515.27	-564.23	-165.91	-212.83	-131.24	-46.6	-26	-18.86
Free Cash Flow Per Share	-5.02	-4.86	-6.68	-2.21	-3.42	-2.41	-3.36	-3.08	-3.25
Gross Margin	85.25%	92.53%	99.70%	100.00%	-	-	-	-	-
Operating Margin	-130.39%	-788.38%	-805.67%	-85.27%	-	-	-	-	-
Profit Margin	-133.29%	-864.70%	-1121.27%	-137.59%	-	-	-	-	-
Free Cash Flow Margin	-150.13%	-683.18%	-847.66%	-66.19%	-	-	-	-	-
EBITDA	-495.21	-617.39	-731.27	-312.23	-298.83	-124.99	-50.63	-27.12	-46.57
EBITDA Margin	-124.87%	-818.58%	-1098.61%	-124.57%	-	-	-	-	-
Depreciation & Amortization	1.7	1.49	1.49	0.86	0.6	0	0	0	0
EBIT	-496.92	-618.88	-732.76	-313.09	-299.42	-124.99	-50.63	-27.12	-46.57
EBIT Margin	-125.30%	-820.55%	-1100.85%	-124.91%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).